HN2007000437A - Compuestos de pirazolina y su uso y composiciones farmaceuticas - Google Patents
Compuestos de pirazolina y su uso y composiciones farmaceuticasInfo
- Publication number
- HN2007000437A HN2007000437A HN2007000437A HN2007000437A HN2007000437A HN 2007000437 A HN2007000437 A HN 2007000437A HN 2007000437 A HN2007000437 A HN 2007000437A HN 2007000437 A HN2007000437 A HN 2007000437A HN 2007000437 A HN2007000437 A HN 2007000437A
- Authority
- HN
- Honduras
- Prior art keywords
- pharmaceutical compositions
- pirazoline
- compounds
- pirazoline compounds
- class
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PREENTE INVENCION COMPRENDE UNA CLASE DE COMPUESTOS DE PIRAZOLINA, Y COMPOSICIONES FARMACEUTICAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86360606P | 2006-10-31 | 2006-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2007000437A true HN2007000437A (es) | 2011-01-17 |
Family
ID=39027523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2007000437A HN2007000437A (es) | 2006-10-31 | 2007-10-31 | Compuestos de pirazolina y su uso y composiciones farmaceuticas |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US7781428B2 (es) |
| EP (1) | EP2089367B1 (es) |
| JP (1) | JP4977760B2 (es) |
| KR (1) | KR101107800B1 (es) |
| CN (1) | CN101541757A (es) |
| AP (1) | AP2527A (es) |
| AR (1) | AR063529A1 (es) |
| AT (1) | ATE537151T1 (es) |
| AU (1) | AU2007315884B2 (es) |
| BR (1) | BRPI0717937A2 (es) |
| CA (1) | CA2667966C (es) |
| CL (1) | CL2007003154A1 (es) |
| CO (1) | CO6160307A2 (es) |
| CR (1) | CR10725A (es) |
| CU (1) | CU23779B7 (es) |
| CY (1) | CY1112311T1 (es) |
| DK (1) | DK2089367T3 (es) |
| EA (1) | EA016370B1 (es) |
| ES (1) | ES2375877T3 (es) |
| GE (1) | GEP20115239B (es) |
| GT (1) | GT200700096A (es) |
| HN (1) | HN2007000437A (es) |
| HR (1) | HRP20120078T1 (es) |
| IL (1) | IL198241A0 (es) |
| MA (1) | MA30821B1 (es) |
| MX (1) | MX2009004662A (es) |
| MY (1) | MY145795A (es) |
| NI (1) | NI200900071A (es) |
| NO (1) | NO20091741L (es) |
| NZ (1) | NZ575923A (es) |
| PE (1) | PE20081472A1 (es) |
| PL (1) | PL2089367T3 (es) |
| PT (1) | PT2089367E (es) |
| RS (2) | RS20090208A (es) |
| SI (1) | SI2089367T1 (es) |
| TN (1) | TN2009000160A1 (es) |
| TW (1) | TWI357327B (es) |
| UA (1) | UA92670C2 (es) |
| UY (1) | UY30670A1 (es) |
| WO (1) | WO2008053300A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| KR20130036171A (ko) * | 2009-10-29 | 2013-04-11 | 브리스톨-마이어스 스큅 컴퍼니 | 트리시클릭 헤테로시클릭 화합물 |
| EP2568986B1 (en) | 2010-05-10 | 2016-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| CA2798831A1 (en) | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
| JP6180930B2 (ja) | 2010-06-16 | 2017-08-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 創傷治癒過程における再上皮化を刺激するための方法及び組成物 |
| CN102372710A (zh) | 2010-08-18 | 2012-03-14 | 山东轩竹医药科技有限公司 | 作为盐皮质激素受体拮抗剂的并环类化合物 |
| WO2012048022A2 (en) * | 2010-10-05 | 2012-04-12 | Nova Southeastern University | Methods and compositions for therapeutic modulation of aldosterone levels in heart disease |
| MX367404B (es) | 2014-06-30 | 2019-08-20 | Astrazeneca Ab | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. |
| ES2846835T3 (es) | 2015-10-13 | 2021-07-29 | Inst Nat Sante Rech Med | Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea |
| ES2973248T3 (es) | 2016-07-26 | 2024-06-19 | Inst Nat Sante Rech Med | Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis |
| ES2859478T3 (es) | 2016-09-02 | 2021-10-04 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos sustituidos |
| WO2019032631A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | Oxime ether compounds |
| WO2019032632A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | ALKYLPHENYL COMPOUNDS |
| WO2021180818A1 (en) | 2020-03-11 | 2021-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| US20240366632A1 (en) | 2021-08-31 | 2024-11-07 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of ocular rosacea |
| CN113679716B (zh) | 2021-10-13 | 2024-03-26 | 史大永 | 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用 |
| CN114230457B (zh) * | 2022-01-04 | 2023-06-09 | 中山大学 | 一类2-亚苄基四氢萘酮衍生物及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1086068A (en) * | 1964-09-02 | 1967-10-04 | Ici Ltd | Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein |
| BE789948A (fr) * | 1971-10-13 | 1973-04-11 | Sandoz Sa | Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments |
| US3816438A (en) * | 1972-12-22 | 1974-06-11 | Sandoz Ag | 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles |
| US3843666A (en) * | 1973-05-29 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
| US4866025A (en) * | 1988-09-30 | 1989-09-12 | Eastman Kodak Company | Thermally-transferable fluorescent diphenylpyrazolines |
| ES2098547T3 (es) * | 1992-01-23 | 1997-05-01 | Pfizer | Benzopirano y otros antagonistas de ltb4 relacionados. |
| GB9318691D0 (en) | 1993-09-09 | 1993-10-27 | Merck Sharp & Dohme | Therapeutic agents |
| AR006520A1 (es) | 1996-03-20 | 1999-09-08 | Astra Pharma Prod | Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion. |
| AU711539B2 (en) * | 1996-09-05 | 1999-10-14 | Astra Pharmaceuticals Limited | Novel aryl-pyridazines |
| JPH10273467A (ja) * | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
| IT1292092B1 (it) | 1997-06-05 | 1999-01-25 | Geange Ltd | Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali |
| EP1073435B1 (en) | 1998-04-30 | 2004-07-07 | Abbott GmbH & Co. KG | Substituted tricyclic pyrazole derivatives with protein kinase activity |
| US6432974B1 (en) * | 2000-02-04 | 2002-08-13 | Wyeth | Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor |
| ATE448207T1 (de) | 2002-03-08 | 2009-11-15 | Merck & Co Inc | Mitotische kinesin-hemmer |
| WO2003078394A1 (en) | 2002-03-15 | 2003-09-25 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| AU2003257078B2 (en) | 2002-08-02 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of GSK-3 |
| CA2496295C (en) | 2002-09-18 | 2010-11-23 | Michael John Munchhof | Novels pyrazole compounds as transforming growth factor (tgf) inhibitors |
| JP2007500253A (ja) | 2003-01-22 | 2007-01-11 | イーライ リリー アンド カンパニー | ステロイドホルモン核内受容体のインドール誘導体モジュレーター |
| WO2005066161A1 (en) | 2003-12-19 | 2005-07-21 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
| JP2007230869A (ja) | 2004-04-05 | 2007-09-13 | Takeda Chem Ind Ltd | アルドステロン受容体拮抗剤 |
| WO2006010142A2 (en) | 2004-07-14 | 2006-01-26 | Ligand Pharmaceuticals, Inc. | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use |
| EP1773768B8 (en) | 2004-07-30 | 2018-12-26 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
| AU2006205220B2 (en) | 2005-01-10 | 2012-09-13 | Exelixis, Inc. | Heterocyclic carboxamide compounds as steroid nuclear receptors ligands |
| EP1844768A1 (en) | 2005-01-19 | 2007-10-17 | Dainippon Sumitomo Pharma Co., Ltd. | Aromatic sulfone compound as aldosterone receptor modulator |
| AU2006212863A1 (en) | 2005-02-10 | 2006-08-17 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
-
2007
- 2007-10-17 RS RSP-2009/0208A patent/RS20090208A/sr unknown
- 2007-10-17 MX MX2009004662A patent/MX2009004662A/es active IP Right Grant
- 2007-10-17 AP AP2009004822A patent/AP2527A/xx active
- 2007-10-17 NZ NZ575923A patent/NZ575923A/en not_active IP Right Cessation
- 2007-10-17 WO PCT/IB2007/003207 patent/WO2008053300A1/en not_active Ceased
- 2007-10-17 EP EP07825488A patent/EP2089367B1/en active Active
- 2007-10-17 AU AU2007315884A patent/AU2007315884B2/en not_active Ceased
- 2007-10-17 CA CA2667966A patent/CA2667966C/en not_active Expired - Fee Related
- 2007-10-17 PT PT07825488T patent/PT2089367E/pt unknown
- 2007-10-17 UA UAA200903302A patent/UA92670C2/ru unknown
- 2007-10-17 BR BRPI0717937-5A2A patent/BRPI0717937A2/pt not_active IP Right Cessation
- 2007-10-17 ES ES07825488T patent/ES2375877T3/es active Active
- 2007-10-17 KR KR1020097008836A patent/KR101107800B1/ko not_active Expired - Fee Related
- 2007-10-17 MY MYPI20091613A patent/MY145795A/en unknown
- 2007-10-17 CN CNA2007800433330A patent/CN101541757A/zh active Pending
- 2007-10-17 GE GEAP200711240A patent/GEP20115239B/en unknown
- 2007-10-17 SI SI200730830T patent/SI2089367T1/sl unknown
- 2007-10-17 RS RS20120051A patent/RS52203B/sr unknown
- 2007-10-17 DK DK07825488.5T patent/DK2089367T3/da active
- 2007-10-17 HR HR20120078T patent/HRP20120078T1/hr unknown
- 2007-10-17 PL PL07825488T patent/PL2089367T3/pl unknown
- 2007-10-17 JP JP2009533977A patent/JP4977760B2/ja not_active Expired - Fee Related
- 2007-10-17 AT AT07825488T patent/ATE537151T1/de active
- 2007-10-17 EA EA200970341A patent/EA016370B1/ru not_active IP Right Cessation
- 2007-10-24 US US11/923,248 patent/US7781428B2/en not_active Expired - Fee Related
- 2007-10-29 UY UY30670A patent/UY30670A1/es not_active Application Discontinuation
- 2007-10-29 AR ARP070104787A patent/AR063529A1/es not_active Application Discontinuation
- 2007-10-30 PE PE2007001482A patent/PE20081472A1/es not_active Application Discontinuation
- 2007-10-30 GT GT200700096A patent/GT200700096A/es unknown
- 2007-10-30 TW TW096140838A patent/TWI357327B/zh not_active IP Right Cessation
- 2007-10-31 CL CL200703154A patent/CL2007003154A1/es unknown
- 2007-10-31 HN HN2007000437A patent/HN2007000437A/es unknown
-
2009
- 2009-04-17 CU CU20090058A patent/CU23779B7/es not_active IP Right Cessation
- 2009-04-17 CR CR10725A patent/CR10725A/es not_active Application Discontinuation
- 2009-04-20 IL IL198241A patent/IL198241A0/en unknown
- 2009-04-21 CO CO09040130A patent/CO6160307A2/es unknown
- 2009-04-24 TN TNP2009000160A patent/TN2009000160A1/fr unknown
- 2009-04-29 NI NI200900071A patent/NI200900071A/es unknown
- 2009-04-30 MA MA31831A patent/MA30821B1/fr unknown
- 2009-05-04 NO NO20091741A patent/NO20091741L/no not_active Application Discontinuation
-
2010
- 2010-07-12 US US12/834,117 patent/US20100280016A1/en not_active Abandoned
-
2011
- 2011-10-20 US US13/277,270 patent/US20120035131A1/en not_active Abandoned
-
2012
- 2012-01-23 CY CY20121100076T patent/CY1112311T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2007000437A (es) | Compuestos de pirazolina y su uso y composiciones farmaceuticas | |
| ECSP088759A (es) | Composiciones farmacéuticas | |
| BRPI0810696A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0609802A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| PT1931350E (pt) | Administração de inibidores de dipeptidil peptidase | |
| NO20075628L (no) | Farmasøytiske formuleringer | |
| BRPI0919942A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0907562A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0921375A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0716171A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto. | |
| CR10696A (es) | Compuestos de n-metilaminometil isoindol, composiciones que las comprenden y metodos que utilizan los mismos | |
| BRPI0815709A2 (pt) | composro, composição farmacêutica, e, uso de um composto. | |
| SV2007002427A (es) | Una formulacion solida de dosificacion farmaceutica | |
| BRPI0917315A2 (pt) | anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica | |
| ITBO20050123A1 (it) | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina | |
| RU2398586C3 (ru) | Фармацевтическая композиция | |
| BRPI0921879A2 (pt) | composto, composição farmacêutica , e, uso de um composto | |
| UY31273A1 (es) | Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53 | |
| BRPI0716698A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
| ATE461202T1 (de) | Hiv-integrasehemmer | |
| BRPI0812942A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
| HN2008001393A (es) | Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| HN2009000566A (es) | Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen. | |
| BRPI0906937A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| UY31349A1 (es) | Inhibidores de la interaccion entre mdm2 y p53 |